title: [Effect of sibutramine (meridia) on body composition, peptide YY3-36 and serotonin levels in patients with exogenous constitutional obesity].
abstract: OBJECTIVE
  To evaluate the impact of gradual weight loss and the positive effect of sibutramine on metabolic parameters and the levels of serotonin and neuropeptide YY3-36 levels in patients with exogenous constitutional obesity (ECO).
  
  
  METHODS
  The study included 36 patients (24 women and 12 men; mean age 37.56 +/- 0.9 years) with a verified diagnosis of ECO. The height, body weight, waist and hip circumference (WC and HC), and body mass index (BMI) were determined. Adipose tissue content was estimated by a bioimpedance method using an adipose mass analyzer. Serum peptide YY3-36 levels were measured by enzyme immunoassay and blood serotonin concentrations were estimated by high performance liquid chromatography with an electrochemical method.
  
  
  RESULTS
  12-week sibutramine therapy caused a significant reduction in body weight, WC, HC, and BMI (p < 0.05) in all the patients. At the same time they were found to have a considerable body composition change (total body and visceral fat was decreased, total body water increased, and systemic metabolism was lowered). The mean peptide YY3-36 level was significantly decreased. Sibutramine did not affect the serum content of total serotonin in the sera of patients.
  
  
  CONCLUSIONS
  Sibutramine used in the combined therapy in patients with ECO contributes to an effective and steady-state weight loss. Sibutramine treatment causes a reduction in total neuropeptide YY3-36, systemic metabolism, and adipose tissue at the expense of the visceral depot.
authors.forename: Iu Iu
authors.initials: IuIu
authors.lastname: Vlasova
authors.forename: A S
authors.initials: AS
authors.lastname: Ametov
mesh_terms: D000328:Adult; D000886:Anthropometry; D001067:Appetite Depressants / Q000008:administration & dosage / Q000627:therapeutic use*; D001823:Body Composition / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects; D003131:Combined Modality Therapy; D003503:Cyclobutanes / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009765:Obesity / Q000097:blood / Q000178:diet therapy / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D010446:Peptide Fragments; D019894:Peptide YY / Q000097:blood*; D012701:Serotonin / Q000097:blood*; D016896:Treatment Outcome
chemical_list: D001067:Appetite Depressants; D003503:Cyclobutanes; D010446:Peptide Fragments; D019894:Peptide YY; C061785:peptide YY (3-36); D012701:Serotonin; C058254:sibutramine